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Down Syndrome (DS) is the most frequent genetic cause of intellectual disability with a wide spectrum 
of neurodevelopmental outcomes. At present, the relationship between structural brain morphology 
and the spectrum of cognitive phenotypes in DS, is not well understood. This study aimed to quantify 
the development of the fetal and neonatal brain in DS participants, with and without a congenital 
cardiac defect compared with a control population using dedicated, optimised and motion-corrected 
in vivo magnetic resonance imaging (MRI). We detected deviations in development and altered 
regional brain growth in the fetus with DS from 21 weeks’ gestation, when compared to age-matched 
controls. Reduced cerebellar volume was apparent in the second trimester with significant alteration 
in cortical growth becoming evident during the third trimester. Developmental abnormalities in the 
cortex and cerebellum are likely substrates for later neurocognitive impairment, and ongoing studies 
will allow us to confirm the role of antenatal MRI as an early biomarker for subsequent cognitive ability 
in DS. In the era of rapidly developing technologies, we believe that the results of this study will assist 

















Down Syndrome (DS) is the most common genetic cause of intellectual disability, occurring as a result 
of triplication of a genomic region on human chromosome 21 (Trisomy 21; T21) 1,2. The 
neurodevelopmental phenotype of DS is associated with cognitive deficits with varying degrees of 
impairment of speech, motor and language functions, with a wide and largely unexplained spectrum 
of IQ’s (range = 20-80; mean = 50) 3–6. Approximately 50% of DS babies are born with a congenital 
heart defect (CHD), the most common of which are endocardial cushion defects, including 
atrioventricular septal defects (AVSD; 45%) and ventricular septal defects (VSD; 35%) 7–10. The 
presence of cardiac disease is associated with a poorer outcome, as observed in typically developing 
children with CHD, where studies have shown deficits in neurocognitive, motor and psychosocial 
skills11. Children with DS who have an AVSD have been shown to have poorer gross motor skills, 
cognition and lower scores in expressive and receptive vocabulary, as compared to DS children with a 
structurally normal heart 12–14. However, there is limited information regarding structural brain 
development in the presence or absence of a CHD in DS.   
The severity and range of problems experienced in DS are determined, in part, by overexpression of 
specific genes on the extra chromosome, and dysregulation of their associated pathways 15,16. At 
present, there is little known about early brain growth trajectories in DS and the spectrum of cognitive 
phenotypes. Abnormalities in brain development in DS, such as reductions in cortical and cerebellar 
volumes, have been observed in early life predominantly through post-mortem cases, but there is 
little in vivo information about when atypical brain growth and development patterns may emerge 17. 
Ultrasound studies (US) have concentrated on first trimester findings to assist in early diagnosis 18, 
with a few small sampled studies focusing on the second and third trimester, and noting smaller head 
circumferences and cerebellar diameters 19.   
Previous studies have largely focused on children and adults with DS, which makes it difficult to 
untangle the primary pathophysiological and direct effects of the condition on the brain, from the 
secondary or compensatory mechanisms which arise from living with the disorder. To reduce these 
confounds, a more detailed understanding of early in vivo growth of the cortex and cerebellum, may 
allow us to identify early biomarkers to predict the severity of initial cognitive impairments, and 
improve counselling for prospective parents. It also has the potential to reveal new windows for future 
therapeutic intervention strategies aimed at improving neurodevelopmental outcomes. 
The primary objective of this study was to use MR imaging techniques to investigate the developing 
brain across gestation, in a cohort of fetuses and neonates with DS, with and without a CHD. We aimed 
to objectively quantify three-dimensional (3D) volumetric and two-dimensional (2D) linear 
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measurements of whole brain, cortex and cerebellum and to compare these with aged-matched 
control cases. We hypothesised that there are quantifiable alterations in early cortical and cerebellar 
growth in fetuses and neonates with DS as compared with controls and that these are further altered 
by the presence of a cardiac abnormality.  
 
Methods 
Ethical approval for this study was obtained from the West London and GTAC Research Ethics 
Committee (REC) for DS participants and fetal controls (07/H0707/105); and from the Dulwich NREC 
for neonatal controls (12/LO/2017). Informed consent was obtained from all participants or their legal 
guardians, prior to imaging at Hammersmith Hospital and St. Thomas’ Hospital, London, UK. All 
methods were carried out in accordance with the relevant guidelines and regulations.  
Participants 
Pregnant women with a fetus diagnosed with DS or with a high risk for DS were referred from 
antenatal and fetal medicine clinics across London hospitals, following their anomaly scans, 
amniocentesis, or blood test results.  Ex-fetal participants who consented during their initial scan to 
be contacted post-delivery, were invited for a neonatal scan up to 46 weeks post-menstrual age 
(PMA). Additionally, neonates with confirmed DS were recruited from the neonatal unit or postnatal 
wards at St Thomas’ Hospital. Participants with DS and other non-brain congenital abnormalities such 
as CHDs or gastrointestinal malformations were also included in this study. The presence and 
characteristics of any antenatally detected CHD were confirmed on echocardiography postnatally as 
part of a routine clinical assessment. Clinical details for all fetuses and neonates with DS can be found 
in Supplementary Table 1. Cases with any overt malformations as detected on MRI were excluded. 
Healthy pregnant volunteers were recruited from the antenatal clinics at Queen Charlotte’s and 
Chelsea Hospital and St. Thomas’ Hospital, London at the time of their anomaly scans (approximately 
20 weeks’ gestational age (GA)) or self-referred.  The entry criterion for a low risk fetal control for this 
study, was a normal brain appearance as determined by fetal MRI and confirmed by an experienced 
perinatal neuroradiologist. Fetuses with other congenital or chromosomal abnormalities, women with 
a history of drug use, twin pregnancies, pregnancies with delivery complications resulting in neonatal 
neurological complications were excluded from the study. In addition, fetal participants with an 
abnormal appearance of the brain on neonatal MRI, birth weight below the 3rd centile, premature 
birth (<37 weeks GA), sub-optimal MR image quality and with an abnormal outcome at either the year 
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1 or 2 neurodevelopmental assessments were also excluded. Control group neonates were only 
recruited from South London and South East of England antenatal centres as part of the Brain Imaging 
in Babies Study (BIBS), and scanned at the Centre for the Developing Brain (St. Thomas’ Hospital, 
London). Neonates were included based on a normal neonatal brain appearance on MRI, classified as 
having no structural anomalies and no clinically significant acquired findings, with no other congenital 
or chromosomal abnormalities, and a normal neurodevelopmental outcome at 2 years of age.  
Fetal Image Acquisition 
Fetal MRI was performed on a 1.5-Tesla (1.5T) or 3-Tesla (3T) MRI System (Philips Achieva; Philips 
Medical Systems, Best, The Netherlands) using a 32-channel cardiac array coil placed around the 
maternal abdomen.  Participants were scanned in either left lateral or supine position and provided 
with a pregnancy pillow and foam wedges for comfort. Maternal temperature was taken before and 
after the scan, and maternal heart rate was monitored throughout. Sedatives were not administered 
and the total scan time was restricted to 60 minutes. All fetal control data was acquired on a 1.5T 
scanner; fetal DS patients were scanned on a combination of 1.5T (n=12) and 3T scanners (n=18). 
Fetal T2-weighted images were acquired in the transverse, sagittal and coronal plane using single shot 
turbo spin echo (ssTSE) sequences with the following scanning parameters:                                                      
repetition time (TR) = 15 s; echo time (TE) = 160 ms; slice thickness = 2.5 mm with a slice overlap = 1.5 
mm; and flip angle = 90 degrees. The brain was oversampled by acquiring multiple overlapping single 
shot T2-weighted images to ensure complete coverage of all regions of interest within the brain. The 
TR on the 1.5T and 3T scanners was determined by the B1 amplitude. The TE was the same on both 
scanners. 
3D reconstructed images were obtained using Snapshot MRI with Volume Reconstruction (SVR) from 
2D slices  20,21.  A stack of images with the least motion and artefacts was selected as the target, and a 
mask was created to isolate the fetal brain from surrounding maternal and extracranial fetal tissue, 
using ITK-SNAP (version 2.4.0; Yushkevich et al. 2006) 22. The optimised reconstruction algorithm used 
intensity matching to exclude mis-registered or corrupted voxels and slices. The approved slices were 
registered into a common coordinate space for alignment, to produce the resultant high signal-to-
noise ratio images. The reconstructed brains were manually re-orientated and then resampled from 
1.25 x 1.25 x 1.25mm to a voxel size of 0.2 x 0.2 x 1 mm, to improve the resolution of smaller structures 
23.  The datasets provide complete coverage of the brain in the orthogonal planes, which is optimum 
for detailed volumetric analysis.  
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Neonatal Image Acquisition 
Neonatal MR scanning was performed on a Philips Achieva 3-Tesla system (Best, The Netherlands) at 
the Centre for the Developing Brain (St. Thomas’ Hospital, London) using a dedicated 32 channel 
neonatal head coil.  Infants were placed and secured within the scanning shell and a neonatal 
positioning device was used to stabilise the head to reduce movement 24. Auditory protection was 
comprised of earplugs moulded from silicone-based putty placed in the outer ear (President Putty, 
Coltene/Whaledent Inc., OH, USA), neonatal earmuffs over the ear (MiniMuffs, Natus Medical Inc., 
CA, USA) and an acoustic hood placed over the scanning shell. Sedation was not administered and all 
babies were scanned during natural sleep. Scan time was restricted to 60 minutes. An experienced 
neonatologist was present during the examinations and pulse oximetry, heart rate, and temperature 
were monitored throughout the scan. 
T2-weighted images were acquired in the sagittal and transverse planes using a multi-slice turbo spin 
echo sequence. Two stacks of 2D slices were acquired using the scanning parameters: TR = 12 s; TE = 
156 ms; slice thickness = 1.6 mm with a slice overlap = 0.8 mm; flip angle = 90 degrees and an in-plane 
resolution: 0.8x0.8 mm.  
Visual analysis of all fetal and neonatal images was performed by a specialist perinatal radiologist to 
exclude additional anomalies and confirm appropriate appearance for gestation. Image datasets 
showing an overt additional malformation were excluded. All T2-weighted images were reviewed to 
assess image quality and those with excessive motion, which could not be automatically accurately 
segmented, were excluded. As such, three fetal cases were excluded as they could not be 




Fetal and neonatal brain linear measurements were performed on reconstructed images using ImageJ 
(version 1.46R, National Institutes of Health, Bethesda, MD, USA), and based on the following 
parameters 23,25. Figure 1; (a) Biparietal diameter (BPD) brain – maximum brain width in the transverse 
plane, outermost to outermost edge; (b) Biparietal diameter (BPD) skull – the widest diameter of the 
fetal skull measured in the transverse plane, outermost to innermost edge; (c) Occipitofrontal 
diameter (OFD) brain – the maximum distance of the brain width between the frontal and occipital 
lobes, measured in the sagittal plane, outermost to outermost edge; (d) Occipitofrontal diameter 
(OFD) skull – the maximum distance between the frontal and occipital skull bones, measured in the 
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sagittal plane, outermost to innermost edge (e) Cavum width - largest width in the transverse plane; 
(f) Head circumference (HC) – calculated using the equation: head circumference = 1.62 x [(skull BPD) 
+ (skull OFD)]; (g) Transcerebellar diameter (TCD) – the maximum lateral cerebellar distance in the 
transverse plane. All vermis measurements were taken in the mid-sagittal plane, (h) Vermis height – 
the maximum superior-inferior length; (i) Vermis width – the maximum distance between the 
fastigium and the posterior part of the vermis; and (j) Vermis area – calculated using a free hand 
drawing tool.  
 
 
Figure 1: Visual representation of linear measurements in the fetal brain in the axial plane (a: BPD – brain, b: 
BPD – skull, c: OFD – brain, d: OFD – skull, e: cavum width, f: HC, g: TCD; h: vermis height; i: vermis width; j: 
vermis surface area). 
Fetal volumetric segmentation  
Volumetric segmentation of the supratentorial brain tissue, lateral ventricles and extra-cerebral CSF 
(eCSF) was performed in a semi-automated manner, whilst the cortex and cerebellum were manually 
segmented using ITK-SNAP 22 using the following parameters; (a) Supratentorial brain tissue volume - 
brain tissue above the tentorium, excluding the brainstem, cerebellum and any CSF spaces; (b) Cortical 
volume - total cerebral cortical grey matter; (c) Total ventricular volume - combined  volumes of the 
left and right ventricles, including the choroid plexus, but excluding the third and fourth ventricle, the 
cavum septum pellucidum and cavum vergae (CSP); (d) eCSF volumes - all the intracranial CSF spaces 
surrounding the supratentorial brain tissue and cerebellum and including the interhemispheric fissure 
but not any ventricular structure, the CSP or vergae; and (e) Total cerebellar volume -  both cerebellar 
hemispheres and the vermis and excluding the pons and fourth ventricle (Fig. 2a-e). To ensure 
compatibility between volumetric data acquired from 1.5T and 3T reconstructions, a healthy pregnant 
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volunteer was scanned on both scanners on the same day. Volumetric data were compared and no 
significant differences were found between the two images across any of the key fetal brain 
segmentation regions; volumes were within the excepted +/-5% threshold.  
Figure 2: Volumetric segmentation of the fetal brain. Segmentation of T2-weighted volumetric MR images in the 
axial, sagittal and coronal planes showing (a) supratentorial brain tissue (red), (b) cortex (green), (c) lateral 
ventricles (dark blue), (d) extra cerebral cerebrospinal fluid (light blue); and (e) cerebellar hemispheres (pink), 
cerebellar vermis (bright green), pons (yellow) and fourth ventricle (blue). 
Neonatal volumetric segmentation  
T2-weighted images were segmented using The Developing Brain Region Annotation With 
Expectation-Maximization (Draw-EM) MIRTK Package, a fully automated tissue segmentation 
algorithm, optimised for the neonatal brain 26. Tissue segmentations were visually inspected for 
accuracy and any mislabelled voxels were manually edited using ITK-SNAP. Volumetric analysis was 
performed on supratentorial brain tissue, cortical, cerebellar, eCSF and lateral ventricular volumes. 
Supratentorial brain tissue volumes were calculated by the sum of cortical grey matter, deep grey 




Figure 3: Volumetric segmentation of the neonatal brain. (a) Reconstructed T2 neonatal brain, (b) automatic 
neonatal brain segmentation; supratentorial brain tissue (bright blue + green + grey), cortex (green), lateral 
ventricles (light blue), extra cerebral cerebrospinal fluid (red), cerebellar hemispheres (pink); and brainstem 
(deep blue).  
Statistical analysis 
Statistical analysis was performed using the SPSS software package (SPSS Chicago, IL, USA; version 24) 
and MATLAB (Release: 2017a, The MathWorks, Inc., Natick, MA, USA), and visualised using GraphPad 
Prism (GraphPad software, La Jolla, CA, USA; version 8.00).  Each variable was tested for normality, 
non-normally distributed data were log-transformed. Linear and volumetric measurements for the 
combined fetal and neonatal cohorts were analysed using nested random effects in a fit random 
intercept linear mixed-effects model (LME) to compare results between the two groups (DS and 
controls), controlling for the covariate GA/PMA as a fixed effect, and with a subject dependent random 
effect for the intercept to account for repeated measures. GA/PMA is a continuous variable 
throughout our analyses. Cohen’s d values were obtained to assess effect sizes and the magnitude of 
interactions 27,28. Effect sizes were interpreted as small (Cohen’s d value ≤ 0.4), medium (0.5 - 0.7) and 
large (≥ 0.8) 27. A post-hoc False Discovery Rate (FDR) test was performed for multiple comparisons, 
using the Benjamini-Hochberg (1995) procedure 29, controlling the alpha error to 5%. Correlations 
were assessed using the Pearson’s correlation coefficient (Pearson’s r) on normally distributed data 
and the Spearman’s correlation coefficient (Spearman’s r) on non-normally distributed data.  
All image analysts (PP, VK, AD and EA) were required to perform linear measurements and volumetric 
analyses in a sub-cohort of ten fetuses. Cases were selected to span the gestational period studied 
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(GA 21.71, 22.86, 25.29, 26.14, 28.29, 29.57, 31.71, 32.71, 34, and 36 weeks). All results were checked 
and verified by the most experienced observers. The inter-rater and intra-rater variability was 
assessed for each region of interest and the threshold for differences was set at +/- 5%. If concordance 
was not reached, the analyses was repeated across all regions of interest until all results were within 
the 5% threshold. Observers were not blinded to cases as control cases had previously been analysed.  
Results 
Control Cohort 
A total of 52 control fetuses (GA at scan: mean (range) - 29.58 (22.43 – 38.86) weeks), and 21 control 
neonates (PMA at scan: mean (range) 41.58 (38-46) weeks) were included as part of this study (Table 
1). The control neonatal cohort was comprised of 11 male and 10 female participants. We were unable 
to obtain the sex ratio for the control fetal cohort, as sex was not documented at the time of scan.  
DS cohort 
30 fetuses with DS, of which 17 fetuses with cardiac defects (GA at scan: mean (range) - 29.28 (21.86-
35.71) weeks) and 13 without cardiac defects (GA at scan: mean (range) - 30.82 (22.14-35.43) weeks) 
were included in the study. Six fetuses (GA range at scan: 21.86-35.71 weeks) were scanned again as 
neonates (PMA range at scan: 39.00-44.57).  
21 neonates with DS were scanned; 16 with cardiac defects (PMA at scan: mean (range) - 40.51 (36-
46) weeks) and 5 without cardiac defects (PMA at scan: mean (range) - 42.20 (39-44) weeks). Of these 
21 DS neonates, 11 were born at term (GA at birth: 37-41.71 weeks) and imaged between 37.57-45.57 
weeks PMA; the other 10 neonates were born prematurely (GA at birth: 31.43-36.71 weeks) and 
scanned between 32.43-44.57 weeks PMA (Table 1). 
The DS cohort was comprised of 21 male and 23 female participants (Supplementary Table 1). The 
first line of analysis aimed to compare regional brain volumes between the DS cohort and the controls 
during the second trimester (GA < 28 weeks), and in the combined third trimester and neonatal period 
(GA>28 weeks) (Table 1).  As 10 of our neonates were born prematurely and scanned shortly after 
birth, and therefore not at term equivalent age, we felt it was appropriate to include these in our 
grouped analysis alongside third trimester fetuses. Secondary analysis was performed to investigate 
the effect of a CHD on regional brain volumes in the DS cohort – cohorts were examined as a whole 




 Control DS 
 GA < 28 weeks GA > 28 weeks GA < 28 weeks GA > 28 weeks 
Total number N = 21 N=52 N = 10 N = 41 
GA/PMA range 
(weeks) 
22.43-27.57 28-45 21.86-27.14 28.14-46 
Mean GA/PMA at 
scan (weeks) 
25.07 36.05 25.22 36.71 
Table 1: Combined fetal and neonatal DS and control cohorts, pre and post 28 weeks’ gestational age (GA); post-
menstrual age (PMA) 
 
 DS  
 Cardiac abnormalities 
 (DS + CHD) 
Non-cardiac  
(DS – CHD) 
Total number N = 33 N = 18 
GA/PMA range (weeks) 21.86-46 22.14-44 
Mean GA/PMA at scan (weeks) 34.72 33.98 
Table 2: Summary of the DS cohort, with and without a congenital heart defect (CHD) 
Results are presented by region of interest, starting with whole brain and cortical measures, followed 











Whole brain and cortical development 
All volumetric and linear brain and skull measures were positively correlated with increasing GA (Fig 
3). Fetuses and neonates with DS were found to have significantly smaller whole brain volumes in the 
second and third trimester, and postnatally (supratentorial brain tissue (p < 0.001, d = 1.64/1.74); 
Table 3 & 4, Fig. 4a).  However, cortical volumes only started to deviate from the normal cohort in the 
third trimester (p < 0.001), after 28 weeks GA (Table 3, Fig. 4b).  No differences in whole brain or 
cortical volumes were found between the DS fetuses and neonates with a congenital cardiac defect 
(DS + CHD) and those without (DS – CHD).  
Fetuses and neonates with DS had significantly smaller brain OFD (p < 0.001, Fig 4f), in the second and 
third trimester compared to age matched controls. Skull OFD (p < 0.001, Fig 4e) and HC (p < 0.001, Fig 
4g) were only found to be significantly smaller in the third trimester, from 28 weeks GA (Table 3; Fig. 
4). Skull and brain BPD were not significantly different between the two cohorts at any time point. 
There were no significant differences in 2D linear measurements between the DS fetuses with and 
without cardiac abnormalities (Table 4). No significant differences were found in whole brain and 
cortical measures between DS males and females when corrected for multiple comparisons.  
13 
 
Figure 4: 2D and 3D regional measures of the brain in fetuses and neonates with DS and a congenital heart defect 
(DS+CHD; red circles), DS without a congenital heart defect (DS–CHD; Blue squares), and age-matched normal 
controls (black triangles). (a) Whole brain volumes, (b) Cortical volumes, (c) Biparietal diameter (BPD) - skull, (d) 
Biparietal diameter (BPD) - brain, (e) Occipitofrontal diameter (OFD) – skull, (f) Occipitofrontal diameter (OFD) - 




2D and volumetric cerebellar measurements in the DS cohort were significantly smaller than in the 
control population; cerebellar volume (p < 0.001), transcerebellar diameter (TCD) (p < 0.001), vermis 
height, width and surface area (p < 0.001) (Table 3; Fig. 5). Cerebellar volumes, vermis height and 
surface area were consistently smaller in the DS cohort, during the second trimester. The TCD and 
vermis width, however, were only smaller in the DS cohorts from the third trimester. We observed 
large effect sizes across all cerebellar measures throughout the third trimester and postnatally (Table 
3). Cerebellar volumes in late gestation DS fetuses and neonates were disproportionately smaller with 
respect to whole brain volumes, compared to the control population. These group differences 
remained significant when cerebellar volumes were corrected for cortical volume and head 
circumference. No differences in cerebellar measures were found in the DS cohort with a CHD, 
compared to those without a CHD (Table 4). Visually, there appear to be differences in the overall 
growth trajectories between DS + CHD compared to DS – CHD, however these were not found to be 
statistically significant.  No significant differences were found in cerebellar measures between DS 
males and females when corrected for multiple comparisons. 
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Figure 5: 2D and 3D measures of the cerebellum in fetuses and neonates with DS and a congenital heart defect 
(DS+CHD; red circles), DS without a congenital heart defect (DS–CHD; blue squares), and age-matched normal 
controls (black triangles). (a) Cerebellar volume, (b) Transcerebellar diameter, (c) Vermis height (d) Vermis width, 








Cerebrospinal Fluid (CSF) regions  
Lateral ventricular volumes were larger in DS cases compared to controls throughout the second and 
third trimester, with a large observed effect size (p < 0.001, d= -1.5/-1.6; Table 3, Fig 6a). Extra cerebral 
CSF (eCSF; Fig 6b) volumes and cavum pellucidum width were not significantly different (p > 0.05) 
(Table 3, Fig. 6). No significant differences were found in those DS cases with a CHD, compared to 
those without. Additionally, no significant differences were found in CSF measures between DS males 




Figure 6: 2D and 3D measures of the CSF regions in fetuses and neonates with DS and a congenital heart defect 
(DS + CHD; red circles), DS without a congenital heart defect (DS – CHD; blue squares), and age-matched normal 


















































Whole brain and cortex 
Whole brain 
(cm3) 
19.06 53.02 4.48 6.40 27 91 4.25 8.29 <0.001 <0.001 1.64 1.74 
Cortex (cm3) 0.75 17.41 1.06 3.93 27 91 0.71 4.42 0.54 <0.001 0.27 0.93 
BPD Skull (mm) -0.65 0.80 1.49 0.88 27 91 -0.44 0.90 0.69 0.44 -0.17 0.19 
BPD Brain (mm) 2.63 1.30 1.21 0.81 27 91 2.17 1.61 0.06 0.14 0.83 0.34 
OFD Skull (mm) 2.46 4.72 1.35 1.02 27 91 1.83 4.64 0.11 <0.001 0.70 0.97 
OFD Brain (mm) 4.67 6.81 1.28 1.03 27 91 3.65 6.63 <0.001 <0.001 1.40 1.39 
HC (mm) 2.92 8.95 4.27 2.68 27 91 0.68 3.33 0.54 <0.001 0.26 0.70 
Cerebellum 
Cerebellum (cm3) 0.58 4.99 0.21 0.51 27 91 2.77 9.84 0.02 <0.001 1.06 2.06 
TCD (mm) 1.12 2.22 0.65 0.45 27 91 1.73 4.91 0.12 <0.001 0.67 1.03 
Vermis height 
(mm) 
2.66 3.41 0.36 0.39 27 91 7.36 8.73 0.00 <0.001 2.83 1.83 
Vermis width 
(mm) 
0.60 1.67 0.38 0.36 27 91 1.59 4.59 0.15 <0.001 0.61 0.96 
Vermis surface 
area (mm2) 




-4.46 -3.12 1.49 0.56 27 91 -2.99 -5.55 0.02 <0.001 -1.15 -1.16 
eCSF (cm3) 0.21 3.04 3.29 3.74 27 91 0.06 0.81 0.95 0.48 0.02 0.17 
Cavum width 
(mm) 
0.89 -0.97 0.45 0.45 26 72 1.97 -2.14 0.09 0.06 0.77 -0.51 
Table 3: LME results and Cohen’s d values for 2D and 3D brain measures comparing the control vs DS cohort: *= 
significant result, p < 0.05. Biparietal diameter (BPD), Occipitofrontal diameter (OFD), Head Circumference (HC), 
and Transcerebellar diameter (TCD), Effect sizes interpreted as small (Cohen’s d = ≤ 0.4), medium (0.5 - 0.7) and 













df t value  p value  Cohen's d 
Whole brain and cortex             
Whole brain (cm3) 13.89 8.75 48 1.59 0.28 0.46 
Cortex (cm3) 0.39 6.11 48 0.06 0.95 0.02 
BPD Skull (mm) 3.42 1.52 48 2.25 0.20 0.65 
BPD Brain (mm) 3.08 1.49 48 2.07 0.20 0.60 
OFD Skull (mm) 2.49 1.77 48 1.41 0.28 0.41 
OFD Brain (mm) 2.74 1.80 48 1.52 0.28 0.44 
HC (mm) 9.53 4.84 48 1.97 0.23 0.57 
Cerebellum             
Cerebellum (cm3) 0.57 0.63 48 0.90 0.50 0.26 
TCD (mm) 0.68 0.72 48 0.95 0.50 0.27 
Vermis height (mm) 0.23 0.59 48 0.39 0.70 0.11 
Vermis width (mm) 0.96 0.58 48 1.64 0.28 0.47 
Vermis surface area 
(mm2) 5.91 12.61 48 0.47 0.76 0.14 
CSF spaces             
Lateral Ventricles (cm3) 3.24 1.31 48 2.48 0.20 0.72 
eCSF (cm3) 7.65 5.53 48 1.38 0.28 0.40 
Cavum width (mm) -0.25 0.66 34 -0.38 0.76 -0.13 
Table 4: LME results and Cohen’s d values for 2D and 3D measures comparing the DS-CHD vs DS+CHD cohort: *= 
significant result, p < 0.05. Biparietal diameter (BPD), Occipitofrontal diameter (OFD), Head Circumference (HC), 
and Transcerebellar diameter (TCD). Effect sizes interpreted as very small (Cohen’s d = 0.01), small (0.20), 
medium (0.50); large (0.80); very large (1.20); and huge (2.0). 
 
We ran an additional analysis comparing volumetric and linear measures from DS fetal patients 
acquired on the 1.5T (n=12) and 3T (n=18) scanners and found no statistically significant differences, 






Using state-of-the-art in vivo MR imaging, we have identified quantifiable alterations from 21 weeks’ 
gestation in brain development of fetuses and neonates with DS.  This study highlights growth 
trajectories of specific brain structures in the developing DS brain, and more importantly the varying 
time points during gestation when deviations arise. We found early second trimester deviations in 
whole brain and cerebellar volumes, and subsequent third trimester alterations in cortical and 
ventricular volumes, and in overall head circumferences. Despite the noted group-wise differences in 
brain development (DS compared to age-matched controls), we found overlap in almost all assessed 
parameters, highlighting a spectrum of atypical development across the DS cohort. This is of interest 
but perhaps not unexpected given the recognised individual variability in neurodevelopmental 
outcome of DS individuals, as established for instance, by IQ scores 6,30–32.  
This study used in vivo MRI to detect early deviations in cerebellar and cortical growth during DS fetal 
and subsequently neonatal development. We observed large effect sizes associated with global 
decreases in whole brain and cortical volumes in the DS population.  A recent proof-of-principle study 
also observed deviations from 28 weeks GA, which we have confirmed in a larger cohort 33. Decreased 
brain and cerebellar growth between 24 and 40 weeks GA are likely biological substrates for impaired 
neurocognitive abilities in later childhood, especially complex functions relating to planning and 
attention 34. Reductions in brain size and altered cellular configurations, such as aberrant cortical 
lamination, reduction in dendritic ramifications and diminished synaptic formation 35 have all been 
detected post-mortem in DS. More specifically, human post-mortem morphometric and 
ultrastructural studies have shown a 20 - 50% reduction in neurons (from birth until 14 years of age), 
in the granular layers of the cerebral cortex along with an abnormal distribution of neurons in cortical 
layers II and IV 36–38. In addition, studies that assessed dendritic morphology and arborisation in PM 
tissue have found that newborns and older infants with DS had shorter dendrites, a reduction in the 
number of spines and altered neuronal morphology (n=7; 26 weeks GA – 11 months) whilst DS fetuses 
exhibited the same neuronal morphology and dendritic spines as control fetuses 39. It is, therefore, 
likely that the anatomical volumetric reductions demonstrated with in vivo MRI reflect the changes in 
the underlying neurobiology. Decreasing growth trajectories over time, could be indicative of 
detrimental reductions in neuronal proliferation and migration, alterations in dendrite morphology 
and impaired cortical connectivity with increasing age, or even cell death. MRI provides an excellent 
and safe in vivo assessment to monitor these changes across gestation and postnatally.  
Our study also found reduced cerebellar volumes in the DS cohort, with more marked deviations from 
aged-matched controls arising with increasing PMA. This supports findings from previous MRI studies 
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on fetal, infant, child, adolescent and adult DS populations where decreased cerebellar volumes were 
reported 33,40–44. Cerebellar volumetric abnormalities, have previously been associated with cognitive 
functions such as impaired attention, language, abstract reasoning, attention, working memory and 
executive control 45,46. Neurodevelopmental assessments have demonstrated that children with DS 
performed worse than the typically developing children in the spatial-simultaneous working memory 
tasks, attributable to variations in cortical and cerebellar growth 47.  Mouse models of DS have 
implicated the gene Dyrk1A in specific structural and functional cerebellar phenotypes, including 
reduced volume 48. Cerebellar neurons are mainly formed prenatally, with some granule cell layer 
formation postnatally 5. Human post-mortem fetal studies have found evidence of impaired cellular 
formation, in the form of hypocellularity in the DS cerebellum which are the likely underlying cause of 
the gross volume reduction on MRI 49,50. 
TCD measures were found to be reduced in the DS cohort, with a statistically significant reduction in 
the third trimester and postnatally. Smaller TCD measures, acquired from US imaging, have previously 
been reported in DS fetuses 51. We also observed large effect sizes associated with decreased 
cerebellar volumes, which are consistent with reduced TCD results. In addition, reductions in 2D linear 
measurements of vermian height, width and surface area were seen in the DS cerebellum compared 
with controls from 21 weeks GA. Whilst not conventionally performed in clinical practice, the fetal 
cerebellar vermis has successfully been measured on US 52,53, and it is possible that additional vermis 
height measures during the fetal anomaly US scan might increase the non-invasive detection of 
fetuses with DS at an earlier time point.  
We identified reduced 2D brain and skull parameters from as early as the second trimester, in addition 
to an altered ratio of OFD to BPD, which is consistent with previous reports of DS populations having 
a brachycephalic skull.  The brachycephalic skull reflects a similarly shaped brain and is considered to 
be a consequence of relatively smaller frontal lobes in DS 54. Frontal lobe dysfunction and structural 
changes have previously been associated with early manifestations of Alzheimer’s disease in the adult 
DS population 55,56. Further analysis of regional brain volumes in early postnatal development will 
allow us to explore the relationship between frontal lobe development and childhood cognitive 
abilities. However, we emphasize that our data is preliminary, and we are not in a position to make 
any concrete links between results presented here and data obtained on adult patients with 
Alzheimer’s disease. 
The DS cohort had significant lateral ventricular enlargement at both the fetal and neonatal time 
points, compared to controls, as indicated by a large effect size However, eCSF volumes were similar 
between groups across gestation. Previous DS fetal US studies have reported enlargement of the 
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lateral ventricles 57. Isolated fetal ventriculomegaly in non-DS children has been associated with mild 
cognitive impairment 58. Lateral ventricular dilation is known to increase across the lifespan and is 
reflective of atrophy of surrounding brain tissue; this is particularly prominent in adults with 
Alzheimer’s Disease pathology 59. Early ventricular enlargement is, however, likely to be 
developmental in origin. DS murine models have demonstrated that overexpression of the calmodulin 
regulator protein, Purkinje cell protein 4 (Pcp4), contributes to impaired ciliary function in ependymal 
cells and results in brain ventriculomegaly 60. 
Whilst we hypothesised that regional brain volumes would be significantly smaller in the DS cohort 
with a cardiac defect, we did not find statistically significant differences (following correction for 
multiple comparisons) between the DS cohorts with or without a CHD. Abnormalities in brain 
development of fetuses with CHD, have reported increased incidences of ventriculomegaly, without 
evidence of an underlying chromosomal abnormality, 61–63. Our study did not find a statistically 
significant elevation in lateral ventricular volume, despite observing a medium effect size. However, 
when assessing the graphs visually it is evident that a number of cases with increased ventricular 
volumes, are in DS cases without a CHD. Other studies in neonates with CHD have focused on atypical 
growth and development of the cortex, which has been attributed to alterations in cerebral blood flow 
and oxygenation and the presence of transposition of the great arteries (TGA) and hypoplastic left 
heart 64.  The cardiac conditions in our cohort with DS were primarily endocardial cushion defects such 
as AVSD, where antenatal changes in blood flow and oxygenation are less prominent than in TGA 65.  
Previous studies have reported a poorer outcome in individuals with DS who have an associated CHD  
12–14.  More detailed studies of the postnatal brain development in DS with and without a cardiac 
defect may be enlightening, as it is possible that the specific genes responsible for a cardiac 
abnormality in DS may have an additional direct effect on brain development 66.  
The primary limitation of this study is the small sample size of the DS cohort to date. DS pregnancy 
termination statistics were 90% in 2012, as reported by the National Down Syndrome Cytogenetic 
Register in England and Wales 67.  The live-birth rate of DS has remained relatively stable over the last 
30 years 68, consequently we found recruitment to be challenging.  In addition, we combined images 
from a 1.5T and a 3T scanner for fetal imaging (all neonates were imaged on a 3T scanner). Images 
acquired from scanners with a stronger magnetic field and higher quality optimised receiver coils, 
benefit from an increased signal to noise ratio (SNR), consequently there may be differences in the 
acquired resolution and contrast of the resultant reconstruction. Previous studies found that while 
most of the brain was identically classified at the two field strengths, there were some regional 
differences observed 69. Others have reported highly reproducible volumetric data in adults with AD 
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and controls, scanned on 1.5T and 3T scanners 70. Upon closer investigation when comparing DS fetal 
datasets acquired on 1.5T (n=12) and 3T (n=18) scanners, we were able to conclude that there were 
no discernible differences in volumetric data.   
We segmented the cortex in all of our cases, but were not able to delineate the subplate consistently. 
The subplate is a transitional structure which varies across gestational age and progressively merges 
with the underlying white matter as gyrification progresses; unlike the cortex which has a contrasting 
signal and is seen in its entirety at all gestations. Whilst we appreciate the biological and 
developmental importance of the subplate we could not accurately assess its volume with our current 
approach. This however would be of interest for future studies. 
In conclusion, this study has demonstrated alterations in both cortical and cerebellar development 
detectable by in vivo MR imaging in utero from the second trimester. Individuals with DS are now living 
to middle age, with improved quality of life and decreases in early mortality as a consequence of 
medical interventions, and improved surgical repair of CHDs 68,71,72. The majority of individuals with 
DS, however, demonstrate cognitive decline in early adulthood. Strategies to modify this decline are 
already taking place 73–75 with researchers also testing therapeutic interventions to improve early brain 
development which may in turn decrease the likelihood of subsequent declines76. Later 
neurodevelopmental assessments in our cohort will allow us to determine whether deviations in these 
antenatal indices are predictive of severity of subsequent cognitive impairments in DS and thereby 














1. Holtzman, D. The human trisomy 21 brain: insights from mouse models of Down syndrome. 
Ment. Retard. … 72, 66–72 (1996). 
2. Antonarakis, S. E., Lyle, R., Dermitzakis, E. T., Reymond, A. & Deutsch, S. Chromosome 21 and 
down syndrome: from genomics to pathophysiology. Nat. Rev. Genet. 5, 725–38 (2004). 
3. Määttä, T., Tervo-Määttä, T., Taanila, A., Kaski, M. & Iivanainen, M. Mental health, behaviour 
and intellectual abilities of people with Down syndrome. Down Syndr. Res. Pract. 11, 37–43 
(2006). 
4. Rachidi, M. & Lopes, C. Mental retardation in Down syndrome: from gene dosage imbalance 
to molecular and cellular mechanisms. Neurosci. Res. 59, 349–69 (2007). 
5. Bartesaghi, R., Guidi, S. & Ciani, E. Is it possible to improve neurodevelopmental 
abnormalities in Down syndrome? Rev. Neurosci. 22, 419–55 (2011). 
6. Karmiloff-Smith, A. et al. The importance of understanding individual differences in Down 
syndrome. F1000Research 5, 389 (2016). 
7. Hyett, J., Noble, P., Snijders, R., Montenegro, N. & Nicolaides, K. Fetal heart rate in trisomy 21 
and other chromosomal abnormalities at 10–14 weeks of gestation. Ultrasound Obstet. 
Gynecol. 7, 239–244 (1996). 
8. Roizen, N. J. & Patterson, D. Down’s syndrome. Lancet 361, 1281–9 (2003). 
9. Sherman, S., Allen, E. E. G., Bean, L. H. & Freeman, S. B. Epidemiology of Down Syndrome. 
Ment. Retard. Dev. Disabil. 13, 221–227 (2007). 
10. Bergstrom, S. et al. Trends in Congenital Heart Defects in Infants With Down Syndrome. 
Pediatrics 138, 1–9 (2016). 
11. Razzaghi, H., Oster, M. & Reefhuis, J. Long Term Outcomes in Children with Congenital Heart 
Disease: National Health Interview Survey. J. Pediatr. 166, 119–124 (2015). 
12. Visootsak, J. et al. Neurodevelopmental outcomes in children with Down syndrome and 
congenital heart defects. Am. J. Med. Genet. A 155A, 2688–91 (2011). 
13. Visootsak, J., Hess, B., Bakeman, R. & Adamson, L. B. Effect of congenital heart defects on 
24 
 
language development in toddlers with Down syndrome. J. Intellect. Disabil. Res. 57, 887–892 
(2013). 
14. Visootsak, J. et al. Influence of CHDs on psycho-social and neurodevelopmental outcomes in 
children with Down syndrome. Cardiol. Young 26, 250–6 (2016). 
15. Rachidi, M. & Lopes, C. Mental Retardation and Human Chromosome 21 Gene Overdosage : 
From Functional Genomics and Molecular Mechanisms Towards Prevention and Treatment of 
the Neuropathogenesis of Down Syndrome. in Genomics, Proteomics and the Nervous system 
21–86 (2011). doi:10.1007/978-1-4419-7197-5 
16. Guedj, F. et al. An Integrated Human/Murine Transcriptome and Pathway Approach To 
Identify Prenatal Treatments For Down Syndrome. Sci. Rep. 6, 32353 (2016). 
17. Hamner, T., Udhnani, M. D., Osipowicz, K. Z. & Lee, N. R. Pediatric Brain Development in 
Down Syndrome: A Field in Its Infancy. J. Int. Neuropsychol. Soc. 1–11 (2018). 
doi:10.1017/S1355617718000206 
18. Borenstein, M., Dagklis, T., Csapo, B., Sotiriadis, A. & Nicolaides, K. H. Brachycephaly and 
frontal lobe hypoplasia in fetuses with trisomy 21 at 11 + 0 to 13 + 6 weeks. Ultrasound 
Obstet. Gynecol. 28, 870–5 (2006). 
19. Winter, T., Ostrovsky, A., Komarniski, C. & Uhrich, S. Cerebellar and Frontal Lobe Hypoplasia 
in Fetuses with Trisomy 21: Usefulness as Combined US Markers 1. Radiology 533–538 
(2000). 
20. Jiang, S. et al. MRI of Moving Subjects Using Multislice Snapshot Images With Volume 
Reconstruction Adult Brain Studies. IEE Trans. Med. Imaging 26, 967–980 (2007). 
21. Kuklisova-Murgasova, M., Quaghebeur, G., Rutherford, M. a, Hajnal, J. V & Schnabel, J. a. 
Reconstruction of fetal brain MRI with intensity matching and complete outlier removal. 
Med. Image Anal. 16, 1550–64 (2012). 
22. Yushkevich, P. A. et al. User-guided 3D active contour segmentation of anatomical structures: 
Significantly improved efficiency and reliability. Neuroimage 31, 1116–1128 (2006). 
23. Kyriakopoulou, V. et al. Normative biometry of the fetal brain using magnetic resonance 
imaging. Brain Struct. Funct. 222, 2295–2307 (2017). 




25. Salomon, L. J. et al. GUIDELINES Practice guidelines for performance of the routine mid-
trimester fetal ultrasound scan. Ultrasound Obs. Gynecol (2010). doi:10.1002/uog.8831 
26. Makropoulos, A. et al. Automatic whole brain MRI segmentation of the developing neonatal 
brain. IEEE Trans. Med. Imaging 33, 1818–1831 (2014). 
27. Cohen, J. Statistical power analysis for the behavioral sciences. (Lawrence Earlbaum 
Associates, 1988). 
28. Rosenthal, R. & Rosnow, R. Essentials of Behavioral Research: Methods and Data Analysis. 
(McGraw-Hill, 2008). 
29. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful 
Approach to Multiple. Journal of the Royal Statistical Society. Series B (Methodological) 57, 
(1995). 
30. Turner, S. & Alborz, A. Academic attainments of children with Down’s syndrome: A 
longitudinal study. Br. J. Educ. Psychol. 73, 563–583 (2003). 
31. Carr, J. Six weeks to twenty-one years old: A longitudinal study of children with DS and their 
families. J. Child Psychol. Psychiatry 29, 407–431 (1988). 
32. Startin, C. M. et al. The LonDownS adult cognitive assessment to study cognitive abilities and 
decline in Down syndrome. Wellcome open Res. 1, 11 (2016). 
33. Tarui, T. et al. Quantitative MRI Analyses of Regional Brain Growth in Living Fetuses with 
Down Syndrome. Cereb. Cortex 00, 1–9 (2019). 
34. Rathbone, R. et al. Perinatal cortical growth and childhood neurocognitive abilities. 
Neurology 77, 1510–7 (2011). 
35. Becker, L. E., Armstrong, D. L. & Chan, F. Dendritic Atrophy in Children with Down’s 
Syndrome. Ann. Neurol. 20, 520–526 (1986). 
36. Schmidt-Sidor, B., Wisniewski, K., Shepard, T. & Sersen, E. Brain growth in Down syndrome 
subjects 15 to 22 weeks gestational age and birth to 60 months. Clin. Neuropathol. 9, (1990). 
37. Wisniewski, K. Down syndrome children often have brain with maturation delay, retardation 
of growth, and cortical dysgenesis. Am. J. Med. Genet. Suppl. 7, (1990). 
38. Wisniewski, K., Laure-Kamionowska, M. & Wisniewski, H. Evidence of arrest of neurogenesis 




39. Takashima, S., Becker, L. E., Armstrong, D. L. & Chan, F.-W. Abnormal neuronal development 
in the visual cortex of the human fetus and infant and down’s syndrome. Brain Res. 225, 1–21 
(1981). 
40. Aylward, E. H. et al. Cerebellar Volume in Adults with Down Syndrome. Arch. Neurol. 54, 209–
212 (1997). 
41. White, N. S., Alkire, M. T. & Haier, R. J. A voxel-based morphometric study of nondemented 
adults with Down Syndrome. Neuroimage 20, 393–403 (2003). 
42. Haydar, T. F. & Reeves, R. H. Trisomy 21 and early brain development. Trends Neurosci. 35, 
81–91 (2012). 
43. Levman, J. et al. Structural magnetic resonance imaging demonstrates abnormal cortical 
thickness in Down syndrome: Newborns to young adults. NeuroImage Clin. 23, (2019). 
44. Shiohama, T., Levman, J., Baumer, N. & Takahashi, E. Structural Magnetic Resonance Imaging-
Based Brain Morphology Study in Infants and Toddlers With Down Syndrome: The Effect of 
Comorbidities. Pediatr. Neurol. (2019). doi:10.1016/j.pediatrneurol.2019.03.015 
45. Strick, P. L., Dum, R. P. & Fiez, J. A. Cerebellum and Nonmotor Function. Annu. Rev. Neurosci. 
32, 413–434 (2009). 
46. Menghini, D., Costanzo, F. & Vicari, S. Relationship between brain and cognitive processes in 
Down syndrome. Behav. Genet. 41, 381–93 (2011). 
47. Lanfranchi, S., Mammarella, I. C. & Carretti, B. Spatial-simultaneous working memory and 
selective interference in Down syndrome. Child Neuropsychol. 1–9 (2014). 
doi:10.1080/09297049.2014.913557 
48. García-Cerro, S. et al. Overexpression of Dyrk1A Is Implicated in Several Cognitive, 
Electrophysiological and Neuromorphological Alterations Found in a Mouse Model of Down 
Syndrome. PLoS One 9, e106572 (2014). 
49. Guidi, S., Ciani, E., Bonasoni, P., Santini, D. & Bartesaghi, R. Widespread proliferation 
impairment and hypocellularity in the cerebellum of fetuses with down syndrome. Brain 
Pathol. 21, 361–373 (2011). 
50. Baburamani, A. A., Patkee, P. A., Arichi, T. & Rutherford, M. A. New approaches to studying 




51. Reddy, R. H., Prashanth, K. & Ajit, M. Significance of foetal transcerebellar diameter in foetal 
biometry: A pilot study. J. Clin. Diagnostic Res. 11, TC01–TC04 (2017). 
52. Cignini, P. et al. Reference charts for fetal cerebellar vermis height: A prospective cross-
sectional study of 10605 fetuses. PLoS One 11, 1–20 (2016). 
53. Spinelli, M. et al. Fetal Cerebellar Vermis Circumference Measured by 2-Dimensional 
Ultrasound Scan: Reference Range, Feasibility and Reproducibility. Ultrasound Int. Open 02, 
E124–E128 (2016). 
54. Pinter, J. & Eliez, S. Neuroanatomy of Down’s syndrome: a high-resolution MRI study. Am. J. 
… 1659–1665 (2001). 
55. Dykens, E. Psychiatric and behavioral disorders in persons with Down syndrome. Ment. 
Retard. Dev. Disabil. … 13, 272–278 (2007). 
56. Fonseca, L. M., Yokomizo, J. E., Bottino, C. M. & Fuentes, D. Frontal Lobe Degeneration in 
Adults with Down Syndrome and Alzheimer’s Disease: A Review. Dement. Geriatr. Cogn. 
Disord. 41, 123–36 (2016). 
57. Schimmel, M. S. M., Hammerman, C., Bromiker, R. & Berger, I. Third ventricle enlargement 
among newborn infants with trisomy 21. Pediatrics 117, e928-931 (2006). 
58. Beeghly, M. et al. Neurodevelopmental outcome of fetuses referred for ventriculomegaly. 
Ultrasound Obstet. Gynecol. 35, 405–16 (2010). 
59. Koran, M. E. I. et al. Differences in age-related effects on brain volume in Down syndrome as 
compared to Williams syndrome and typical development. J. Neurodev. Disord. 6, 8 (2014). 
60. Raveau, M. et al. Brain ventriculomegaly in Down syndrome mice is caused by Pcp4 dose-
dependent cilia dysfunction. Hum. Mol. Genet. 26, 923–931 (2017). 
61. Khalil, A. et al. Prevalence of prenatal brain abnormalities in fetuses with congenital heart 
disease: a systematic review. Ultrasound Obstet. Gynecol. 48, 296–307 (2016). 
62. Brossard-Racine, M. et al. Prevalence and spectrum of in utero structural brain abnormalities 
in fetuses with complex congenital heart disease. Am. J. Neuroradiol. 35, 1593–1599 (2014). 
63. Mebius, M., Kooi, E., Bilardo, C. & Bos, A. Brain Injury and Neurodevelopmental Outcome in 
Congenital Heart Disease: A Systematic Review. Pediatrics 140, e20164055 (2017). 
28 
 
64. Kelly, C. J. et al. Impaired development of the cerebral cortex in infants with congenital heart 
disease is correlated to reduced cerebral oxygen delivery. Sci. Rep. 7, 1–10 (2017). 
65. Peyvandi, S. & Donofrio, M. Circulatory Changes and Cerebral Blood Flow and Oxygenation 
During Transition in Newborns with Congenital Heart Disease. Semin. Pediatr. Neurol. (2018). 
doi:10.1016/j.spen.2018.05.005 
66. Lana-Elola, E. et al. Genetic dissection of Down syndrome-associated congenital heart defects 
using a new mouse mapping panel. Elife 5, 1–20 (2016). 
67. Morris, J. K. & Springett, A. The National Down Syndrome Cytogenetic Register for England 
and Wales : 2012 Annual Report. 44, 0–31 (2014). 
68. Wu, J. & Morris, J. K. The population prevalence of Down’s syndrome in England and Wales in 
2011. Eur. J. Hum. Genet. 21, 1033–1034 (2013). 
69. West, J., Blystad, I., Engström, M., Warntjes, J. B. M. & Lundberg, P. Application of 
Quantitative MRI for Brain Tissue Segmentation at 1.5 T and 3.0 T Field Strengths. PLoS One 8, 
1–12 (2013). 
70. Roche, F. et al. Reproducibility of intracranial and hippocampal volume quantification at 1.5T 
and 3T MRI: Application to ADNI I. Alzheimer’s Dement. 9, P271 (2013). 
71. Jensen, K. M. & Bulova, P. D. Managing the care of adults with Down’s syndrome. BMJ (2014). 
doi:10.1136/bmj.g5596 
72. Glasson, E. et al. The changing survival profile of people with Down’s syndrome: implications 
for genetic counselling. Clin. Genet. 62, 390–393 (2002). 
73. Livingstone, N., Hanratty, J., Mcshane, R. & Macdonald, G. Pharmacological interventions for 
cognitive decline in people with Down syndrome ( Review ). Cochrane Database Syst. Rev. 
(2015). doi:10.1002/14651858.CD011546.pub2.www.cochranelibrary.com 
74. Gardiner, K. J. Pharmacological approaches to improving cognitive function in Down 
syndrome : current status and considerations. Drug Des. Devel. Ther. 9, 103–125 (2015). 
75. De la Torre, R. et al. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits 
in Down syndrome mouse models and in humans. Mol. Nutr. Food Res. 58, 278–88 (2014). 
76. Stagni, F., Giacomini, A., Guidi, S., Ciani, E. & Bartesaghi, R. Timing of therapies for Down 





We thank the parents and children who participated in this study. The authors gratefully acknowledge 
staff from the Centre for the Developing Brain at King’s College London and the Neonatal Intensive 
Care Unit at St. Thomas’ Hospital. In particular, the research radiologists, radiographers, clinicians, 
neonatal nurses, midwives and the administrative teams. In addition, we wish to thank all our obstetric 
and fetal medicine colleagues from our patient identification sites who have referred participants to 
us.  
This work was supported by the Medical Research Council [MR/K006355/1 and MR/LO11530/1]; 
Rosetrees Trust [A1563], Fondation Jérôme Lejeune [2017b – 1707], Sparks and Great Ormond Street 
Hospital Children’s Charity [V5318]. We also gratefully acknowledge financial support from the 
Wellcome/EPSRC Centre for Medical Engineering [WT 203148/Z/16/Z], the National Institute for 
Health Research (NIHR) Biomedical Research Centre (BRC) based at Guy's and St Thomas' NHS 
Foundation Trust and King's College London and supported by the NIHR Clinical Research Facility (CRF) 
at Guy’s and St Thomas’. The Brain Imaging in Babies (BIBS) team additionally acknowledge support 
from EU-AIMS – a European Innovative Medicines Initiative; and infrastructure support from the 
National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre (BRC) at 
South London and Maudsley NHS Foundation Trust and King's College London. 
The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the 
Department of Health.  
 



























101 21.86 42.71 F AVSD x 
102 22.14   M x VM  
103 22.29   M AVSD x 
104 25.29   F AVSD VM 
105 26    F 
mild tricuspid 
regurgitation and mild 
right/left asymmetry 
x 
106 26.29   M 
coarctation of the 
aorta 
x 
107 26.57   M cardiac asymmetry x 
108 27.14   F x VM 
109 27.29   M Tetralogy of Fallot 
VM and duodenal 
atresia 
112 28.14   M x VM 








115 31 43.00 F 
balanced AVSD and 
right sided aortic arch 
x 
116 31   F x 
Twin case – baby small 
for GA. Other twin is a 
normally developing 
baby 
117 33.29   M x 
VM and oesophageal 
atresia 
118 33.29 41.29 F VSD x 
119 33.57   F x VM 
120 33.86   M VSD x 
121 34.43 44.57 M x x 
122 34.86   M 




123 35   F AVSD x 
124 35.43 39.00 M x duodenal atresia 
201   41.86 M AVSD x 
202   43.43 F x x 
203   40.57 F x duodenal atresia 
204   36.14 F 
VSD and pulmonary 
stenosis 
duodenal atresia 
205   41.43 F AVSD and PDA duodenal atresia 
206   43.00 M ASD Hirschsprung’s 
207   45.57 F Tetralogy of Fallot Hirschsprung’s 
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208   38.43 F 
Tetralogy of Fallot, 
PDA 
x 
209   43.57 F 
AVSD and hypoplastic 
arch 
x 
210   44.57 M x x 
211   44.71 F 
VSD with bidirectional 
shunt and large PDA 
Congenital 
hypothyroidism 
212   32.43 F 
mildly dysplastic aortic 
valve 
x 
213   37.57 M 
AVSD and coarctation 
of the aorta 
x 
214   38.86 M ASD Hirschsprung’s 
215   37.86 F AVSD x 
125 30.57   F AVSD - 
126 31.43   M x x 
127 34.14   M x x 
128 30.14 
  
F x x 
129 30.43   M x x 










Supplementary Table 1: Age at scan and clinical characteristics of fetuses and neonates with DS. Atrioventricular 
septal defect (AVSD), atrial septal defect (ASD), ventricular septal defect (VSD), patent ductus arteriosus (PDA) 
and ventriculomegaly (VM) 
 
 
 
 
